Theralases Lead Photodynamic Compound TLD-1433 Provides New Opportunities in Targeted Cancer Therapy

Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers announced today that Theralase researchers have been invited to present their latest research at the international conference, “Photodynamic Therapy and Photodiagnostics Update” to be held in Kochel am See (near Munich, Germany) on September  18 to 22, 2018.

The “Photodynamic Therapy and Photodiagnostics Update” conference is a highly regarded event in the field of Photo Dynamic Therapy (“PDT”) bringing together researchers and clinicians working in all fields of PDT and Photo Diagnosis (“PD”) to foster scientific development of this technology in the fields of biology and medicine.

Arkady Mandel, MD, PhD, DSc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase said “The latest Theralase sponsored research to be presented titled, “Monitoring of cell metabolism during PDT” authored by Svietlana Kalinina, Lothar Lilge, Arkady Mandel and Angelica Rueck, reveals that Theralase’s lead PDC, TLD-1433, is a highly efficient anti-cancer PDC that is able to detect and/or monitor the oxygenation level in cancerous tumours before and during PDT. This is important because by knowing the oxygen concentration in a hypoxic (low oxygen) cancerous tumour allows the Company the ability to optimize the PDT targeted cancer therapy in their destruction. Hypoxic tumours; include: urothelial carcinoma (bladder cancer) and glioblastoma (brain cancer). Theralase through its sponsored research agreements demonstrates its strong commitment to high level research aimed at optimizing the safety and efficacy of its PDCs. This research, collaborating with some of the leading world-renowned experts, will help to accelerate adoption of PDT for clinical applications. Currently, Theralase is focused on commencing a multicenter Phase II, TLD-1433-PDT efficacy study in Non Muscle Invasive Bladder Cancer (‘’NMIBC”) in Canada, the US and internationally. The promising, six-month data from the Phase Ib clinical study for patients with carcinoma in-situ and/or high grade T1, NMIBC supports our strong belief that Theralase’s technology platform offers a new and advanced treatment option for NMIBC patients, who have exhausted all other available treatment options. TLD-1433 PDT represents a unique approach, using a targeted and patient specific drug and light delivery system.  I believe that Theralase’s anti-cancer PDT technology platform will provide patients who present with various cancers, who have failed to respond to the standard of care treatment, with new hope and a viable alternative therapy”.

About Theralase Technologies Inc.

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.  The Company in its Cool Laser Division designs, manufactures and distributes patented and proprietary super-pulsed cool laser technology for the treatment of knee pain, and in off-label use, the treatment of numerous nerve, muscle and joint conditions.

Additional information is available at www.theralase.com and www.sedar.com .

This news release contains "forward-looking statements" which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding Theralase’s proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would", "could", “should”, "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of Theralase to: successfully fund and complete a Phase II NMIBC clinical study, secure the requisite regulatory approvals to commence a Phase II NMIBC clinical study and implement its development plans. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

1.866.THE.LASE (843-5273)

416.699.LASE (5273)

[email protected]

www.theralase.com

Maximum News Dissemination by FSCwire. https://www.fscwire.com

Copyright © 2018 FSCwire